H2G Green Limited (SGX:5AI)
Singapore · Delayed Price · Currency is SGD 0.0120
0.00 (0.00%)
At close: Aug 8, 2025
Elevation Oncology Income Statement
Financials in millions SGD. Fiscal year is April - March.
Millions SGD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Revenue | 15.46 | 10.15 | 13.65 | 7.19 | 4.75 | Upgrade |
Revenue Growth (YoY) | 52.32% | -25.67% | 89.89% | 51.46% | -38.39% | Upgrade |
Cost of Revenue | 7.74 | 6.19 | 7.89 | 4.19 | 2.58 | Upgrade |
Gross Profit | 7.72 | 3.96 | 5.76 | 3 | 2.17 | Upgrade |
Selling, General & Admin | 15 | 12.34 | 9.75 | 6.12 | 5.64 | Upgrade |
Other Operating Expenses | -0.58 | -0.98 | -0.46 | -0.51 | -0.07 | Upgrade |
Operating Expenses | 14.42 | 11.36 | 9.29 | 5.61 | 5.59 | Upgrade |
Operating Income | -6.7 | -7.4 | -3.53 | -2.61 | -3.43 | Upgrade |
Interest Expense | -0.33 | -0.3 | -0.24 | -0.14 | -0.15 | Upgrade |
Interest & Investment Income | 0.05 | 0.06 | 0 | 0.01 | 0.03 | Upgrade |
Currency Exchange Gain (Loss) | -0.02 | -0 | -0.3 | -0.06 | -0.23 | Upgrade |
Other Non Operating Income (Expenses) | 0 | -0.03 | -0.04 | - | - | Upgrade |
EBT Excluding Unusual Items | -7.01 | -7.68 | -4.11 | -2.81 | -3.78 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 0.01 | 0.04 | - | Upgrade |
Gain (Loss) on Sale of Assets | 0.03 | 0.01 | 0 | - | 0 | Upgrade |
Asset Writedown | -0.53 | -1.34 | -0.5 | - | - | Upgrade |
Other Unusual Items | 0.02 | - | - | - | 0.6 | Upgrade |
Pretax Income | -7.48 | -9.01 | -4.6 | -2.76 | -3.18 | Upgrade |
Income Tax Expense | - | -0.1 | - | - | - | Upgrade |
Earnings From Continuing Operations | -7.48 | -8.91 | -4.6 | -2.76 | -3.18 | Upgrade |
Net Income to Company | -7.48 | -8.91 | -4.6 | -2.76 | -3.18 | Upgrade |
Minority Interest in Earnings | 3.64 | 2.94 | 1.28 | - | - | Upgrade |
Net Income | -3.84 | -5.96 | -3.32 | -2.76 | -3.18 | Upgrade |
Net Income to Common | -3.84 | -5.96 | -3.32 | -2.76 | -3.18 | Upgrade |
Shares Outstanding (Basic) | 1,401 | 1,289 | 1,009 | 690 | 577 | Upgrade |
Shares Outstanding (Diluted) | 1,401 | 1,289 | 1,009 | 690 | 577 | Upgrade |
Shares Change (YoY) | 8.69% | 27.71% | 46.35% | 19.42% | 3.57% | Upgrade |
EPS (Basic) | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | Upgrade |
EPS (Diluted) | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | Upgrade |
Free Cash Flow | -7.82 | -10.27 | -4.62 | -1.5 | -2.19 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | Upgrade |
Gross Margin | 49.91% | 38.98% | 42.19% | 41.71% | 45.65% | Upgrade |
Operating Margin | -43.36% | -72.96% | -25.83% | -36.30% | -72.16% | Upgrade |
Profit Margin | -24.84% | -58.76% | -24.29% | -38.45% | -66.88% | Upgrade |
Free Cash Flow Margin | -50.60% | -101.19% | -33.86% | -20.91% | -46.17% | Upgrade |
EBITDA | -4.79 | -6.47 | -2.98 | -2.49 | -3.26 | Upgrade |
EBITDA Margin | -30.98% | -63.73% | -21.83% | -34.60% | -68.72% | Upgrade |
D&A For EBITDA | 1.91 | 0.94 | 0.55 | 0.12 | 0.16 | Upgrade |
EBIT | -6.7 | -7.4 | -3.53 | -2.61 | -3.43 | Upgrade |
EBIT Margin | -43.36% | -72.95% | -25.83% | -36.30% | -72.16% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.